- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharmaron Beijing Co Ltd (300759)
Pharmaron Beijing Co Ltd stock price live, this page displays SZ 300759 stock exchange data. View the 300759 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pharmaron Beijing Co Ltd real time stock price chart below.
What Is the Pharmaron Beijing Co Ltd Stock Price Today?
The Pharmaron Beijing Co Ltd stock price today is 46.42.
What Is the Stock Symbol for Pharmaron Beijing Co Ltd?
The stock symbol for Pharmaron Beijing Co Ltd is "300759."
What Stock Exchange Does Pharmaron Beijing Co Ltd Trade On?
Pharmaron Beijing Co Ltd is listed and trades on the Shenzhen stock exchange.
Is Pharmaron Beijing Co Ltd a Good Stock to Buy?
Determining whether Pharmaron Beijing Co Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300759 quote. (ISIN: CNE100003JW4)
What Is the Pharmaron Beijing Co Ltd Stock Price Today?
The Pharmaron Beijing Co Ltd stock price today is 46.42.
What Is the Stock Symbol for Pharmaron Beijing Co Ltd?
The stock symbol for Pharmaron Beijing Co Ltd is "300759."
What Stock Exchange Does Pharmaron Beijing Co Ltd Trade On?
Pharmaron Beijing Co Ltd is listed and trades on the Shenzhen stock exchange.
Is Pharmaron Beijing Co Ltd a Good Stock to Buy?
Determining whether Pharmaron Beijing Co Ltd, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 300759 quote. (ISIN: CNE100003JW4)
46.42
+1.56(+3.48%)
Closed·
Fair Value
An estimate of a Pharmaron Beijing's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.75
46.96
52 wk Range
21.01
53.57
300759 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Pharmaron Beijing's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.7546.96
52 wk Range
21.0153.57
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.45%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.45%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
300759 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Pharmaron Beijing's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
48.63
Upside
+4.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
9 Buy
2 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 48.63
(+4.75% Upside)
Earnings
Latest Release
Aug 20, 2026
EPS / Forecast
0.23 / 0.25
Revenue / Forecast
4.02B / 3.85B
Compare 300759 to Peers and Sector
Metrics to compare | 300759 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300759PeersSector | |
|---|---|---|---|---|
P/E Ratio | 44.2x | 38.1x | −0.4x | |
PEG Ratio | 2.05 | 0.90 | 0.00 | |
Price/Book | 4.6x | 3.8x | 2.6x | |
Price / LTM Sales | 5.0x | 6.6x | 3.1x | |
Upside (Analyst Target) | 2.9% | 5.7% | 49.3% | |
Fair Value Upside | Unlock | 6.1% | 6.7% | Unlock |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pharmaron Beijing (300759) Stock Price Today?
The Pharmaron Beijing stock price today is 46.42 CNY.
What Stock Exchange Does Pharmaron Beijing Trade On?
Pharmaron Beijing is listed and trades on the Shenzhen Stock Exchange.
What Is the Stock Symbol for Pharmaron Beijing?
The stock symbol for Pharmaron Beijing is "300759."
What Is the Pharmaron Beijing Market Cap?
As of today, Pharmaron Beijing market cap is 75.78B CNY.
What Is Pharmaron Beijing's Earnings Per Share (TTM)?
The Pharmaron Beijing EPS (TTM) is 0.95.
When Is the Next Pharmaron Beijing Earnings Date?
Pharmaron Beijing will release its next earnings report on Oct 22, 2026.
From a Technical Analysis Perspective, Is 300759 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Pharmaron Beijing Stock Split?
Pharmaron Beijing has split 2 times.
How Many Employees Does Pharmaron Beijing Have?
Pharmaron Beijing has 27316 employees.
What is the current trading status of Pharmaron Beijing (300759)?
As of Aug 25, 2026, Pharmaron Beijing (300759) is trading at a price of 46.42 CNY, with a previous close of 44.86 CNY. The stock has fluctuated within a day range of 43.75 CNY to 46.96 CNY, while its 52-week range spans from 21.01 CNY to 53.57 CNY.
What Is Pharmaron Beijing (300759) Price Target According to Analysts?
The average 12-month price target for Pharmaron Beijing is 48.63 CNY, with a high estimate of 66.94 CNY and a low estimate of 33.8 CNY. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +4.75% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.